[Venous thrombolysis with the recombinant human tissue-type plasminogen activator (rt-PA) during the first 3 hours following acute myocardial infarction. Controlled pilot study with placebo].
Melandri
G
G
Branzi
A
A
Berardi
C
C
Bruscoli
F
F
Tartagni
F
F
Binetti
G
G
Galiè
N
N
Magnani
B
B
Gensini
G F
GF
Abbate
R
R
D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010865:Pilot Projects; D010919:Placebos; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use*; D013318:Stroke Volume / Q000187:drug effects
D005343:Fibrinolytic Agents; D010919:Placebos; D010960:Plasminogen Activators
Trombolisi per via venosa mediante l'attivatore tissutale umano ricombinante del plasminogeno (rt-PA) nelle prime tre ore dell'infarto miocardico acuto. Studio pilota controllato con placebo.